Cibisatamab - Roche
Alternative Names: CEA-CD3 TCB; CEA-TCB; RG-7802; RO-6958688Latest Information Update: 18 Sep 2024
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Carcinoembryonic antigen inhibitors; CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 09 Aug 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV)
- 09 Aug 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Recurrent) in Japan (IV)
- 09 Aug 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy, Recurrent) in Japan (IV)